ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026
[Ethanol promotes oxaliplatin resistance in colorectal cancer by activating the TGF‑β/Smad/P21 signaling axis].
Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesTo investigate the effect of ethanol for promoting oxaliplatin resistance in colorectal cancer (CRC) and the underlying molecular mechanisms.
methodsLifetime alcohol consumption data from the PLCO cohort were analyzed to assess the association between alcohol drinking and CRC risk. The differential expressions of alcohol metabolism-related genes between CRC and normal tissues and their associations with recurrence and survival in chemotherapy-treated patients were analyzed based on GEO datasets. Fecal samples from healthy non-drinkers and CRC patients were collected for detecting ethanol levels using gas chromatography-mass spectrometry (GC-MS). In a mouse model bearing subcutaneous CRC xenograft treated with oxaliplatin, the effects of continuous ethanol exposure using the Lieber-DeCarli liquid diet and 4-methylpyrazole (4-MP) treatment on tumor growth were evaluated. In cultured SW480 and HCT116 cells, the effect of 100 and 200 mg/dL ethanol on oxaliplatin sensitivity, apoptosis, cell cycle distribution, and TGF‑β/Smad/P21/Rb axis proteins were analyzed, and the results were further validated with pirfenidone intervention experiment.
resultsHigh-frequency drinkers had a significantly increased risk of CRC. ADH1B and ADH1C were significantly downregulated in CRC tissues, and their low expressions were associated with a higher recurrence rate and poorer overall survival in chemotherapy-treated patients. Ethanol was detected in fecal samples from both healthy individuals and CRC patients. In oxaliplatin-treated tumor-bearing mice, alcohol exposure resulted in a greater tumor volume. In SW480 and HCT116 cells, ethanol significantly increased oxaliplatin IC₅₀, reduced cell apoptosis, induced G0/G1 arrest, decreased S-phase fraction, and upregulated TGF-β1, p-Smad2, and P21 while downregulating p-Rb expression. Pirfenidone partially reversed these changes and attenuated drug resistance of the cells.
conclusionsEthanol accumulation activates the TGF-β/Smad/P21 axis to induce cell cycle arrest and promote oxaliplatin resistance in CRC cells, which can be partially reversed by pirfenidone inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.